The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Lipoprotein Subclasses in the Monitored Atherosclerosis Regression Study (MARS): Treatment Effects and Relation to Coronary Angiographic Progression
Open accessAbstract
Abstract Accumulating evidence suggests that triglyceride-rich lipoproteins contribute to coronary artery disease. Using data from the Monitored Atherosclerosis Regression Study, an angiographic trial of middle-aged men and women randomized to lovastatin or placebo, we investigated relationships between lipoprotein subclasses and progression of coronary artery atherosclerosis. Coronary artery lesion progression was determined by quantitative coronary angiography in low-grade (<50% diameter stenosis), high-grade (≥50% diameter stenosis), and all coronary artery lesions in 220 baseline/2-year angiogram pairs. Analytical ultracentrifugation was used to measure lipoprotein masses that were statistically evaluated for treatment group differences and relationships to progression of coronary artery atherosclerosis. All low density lipoprotein (LDL), intermediate density lipoprotein (IDL), and very low density lipoprotein (VLDL) masses were significantly lowered and all high density lipoprotein (HDL) masses were significantly raised with lovastatin therapy. The mass of smallest LDL (Svedberg flotation rate [S f ] 0 to 3), IDL (S f 12 to 20), all VLDL subclasses (S f 20 to 60, S f 60 to 100, and S f 100 to 400), and peak LDL flotation rate were significantly related to the progression of coronary artery lesions, specifically low-grade lesions. Greater baseline levels of HDL 3 were related to a lower likelihood of coronary artery lesion progression. In multivariate analyses, small VLDL (S f 20 to 60) and HDL 3 mass were the most important correlates of coronary artery lesion progression. These results provide further evidence for the importance of triglyceride-rich lipoproteins in the progression of coronary artery disease. In addition, these results present new evidence for the possible protective role of HDL 3 in the progression of coronary artery lesions. More specific information on coronary artery lesion progression may be obtained through the study of specific apolipoprotein B–containing lipoproteins.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411
Self-citationA prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction.
Stampfer, M. J., Sacks, F. M., Salvini, S., Willett, W. C., & Hennekens, C. H. (1991) · New England Journal of Medicine · doi:10.1056/nejm199108083250601 · Cited by 1,163
Blankenhorn, D. H., Azen, S. P., Kramsch, D. M., Mack, W. J., Cashin-Hemphill, L., Hodis, H. N., DeBoer, L. W. V., Mahrer, P. R., Masteller, M. J., Vailas, L. I., et al. (1993) · Annals of Internal Medicine · doi:10.7326/0003-4819-119-10-199311150-00002 · Cited by 637
Self-citationBlankenhorn, D. H., Alaupovic, P., Wickham, E., Chin, H. P., & Azen, S. P. (1990) · Circulation · doi:10.1161/01.cir.81.2.470 · Cited by 278
Lipoprotein predictors of the severity of coronary artery disease in men and women.
Reardon, M. F., Nestel, P. J., Craig, I. H., & Harper, R. W. (1985) · Circulation · doi:10.1161/01.cir.71.5.881 · Cited by 266
Sweetnam, P. M., Bolton, C. H., Yarnell, J. W., Bainton, D., Baker, I. A., Elwood, P. C., & Miller, N. E. (1994) · Circulation · doi:10.1161/01.cir.90.2.769 · Cited by 98
Cited by
Robins, S. J., Collins, D., Wittes, J. T., Papademetriou, V., Deedwania, P. C., Schaefer, E. J., McNamara, J. R., Kashyap, M. L., Hershman, J. M., Wexler, L. F., et al. (2001) · JAMA · doi:10.1001/jama.285.12.1585 · Cited by 921
Metabolic origins and clinical significance of LDL heterogeneity
Berneis, K. K., & Krauss, R. M. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r200004-jlr200 · Cited by 896
Self-citationJeppesen, J. Ø., Hein, H. O., Suadicani, P., & Gyntelberg, F. (1998) · Circulation · doi:10.1161/01.cir.97.11.1029 · Cited by 676
Herrington, D. M., Howard, T. D., Hawkins, G. A., Reboussin, D. M., Xu, J., Zheng, S. L., Brosnihan, K. B., Meyers, D. A., & Bleecker, E. R. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012952 · Cited by 374
Serum triglycerides as a risk factor for cardiovascular diseases in the Asia-Pacific region.
Asia Pacific Cohort Studies Collaboration (2004) · Circulation · doi:10.1161/01.cir.0000145615.33955.83 · Cited by 358
Freedman, D. S., Otvos, J. D., Jeyarajah, E. J., Barboriak, J. J., Anderson, A. J., & Walker, J. A. (1998) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.18.7.1046 · Cited by 345
Beyond Low-Density Lipoprotein Cholesterol
Arsenault, B. J., Rana, J. S., Stroes, E. S. G., Després, J.-P., Shah, P. K., Kastelein, J. J. P., Wareham, N. J., Boekholdt, S. M., & Khaw, K.-T. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.057 · Cited by 342
Sniderman, A. D., Scantlebury, T., & Cianflone, K. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-135-6-200109180-00014 · Cited by 336
Rosenson, R. S., Otvos, J. D., & Freedman, D. S. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02427-x · Cited by 293
Frohlich, J., & Dobiášová, M. (2003) · Clinical Chemistry · doi:10.1373/clinchem.2003.022558 · Cited by 284
Bays, H. E., Tighe, A. P., Sadovsky, R., & Davidson, M. H. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.3.391 · Cited by 265
Zambon, A., Hokanson, J. E., Brown, B. G., & Brunzell, J. D. (1999) · Circulation · doi:10.1161/01.cir.99.15.1959 · Cited by 263
Low-density lipoprotein size and cardiovascular risk assessment
Rizzo, M., & Berneis, K. (2006) · QJM: An International Journal of Medicine · doi:10.1093/qjmed/hci154 · Cited by 260
Low-Density Lipoprotein Size and Cardiovascular Disease: A Reappraisal
Sacks, F. M., & Campos, H. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030636 · Cited by 241
How Do Elevated Triglycerides and Low HDL-Cholesterol Affect Inflammation and Atherothrombosis?
Welty, F. K. (2013) · Current Cardiology Reports · doi:10.1007/s11886-013-0400-4 · Cited by 221
Joshi, P. H., Khokhar, A. A., Massaro, J. M., Lirette, S. T., Griswold, M. E., Martin, S. S., Blaha, M. J., Kulkarni, K. R., Correa, A., D'Agostino, R. B., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002765 · Cited by 177
Borow, K. M., Nelson, J. R., & Mason, R. P. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.07.035 · Cited by 175
Seshadri, P., Iqbal, N., Stern, L., Williams, M., Chicano, K. L., Daily, D. A., McGrory, J., Gracely, E. J., Rader, D. J., & Samaha, F. F. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.04.009 · Cited by 169
Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes.
Ip, S., Lichtenstein, A. H., Chung, M., Lau, J., & Balk, E. M. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-7-200904070-00007 · Cited by 163
“Smokers, % Lipid Data† Zhao et al, 2003 (32) GE Prospective longitudinal RCT 62 40 74 23 64 (ever smoked) LDL-c: 141 mg/dL Mack et al, 1996 (33) UC Prospective longitudinal RCT 58 15 92 No data 79 (ever smoked) LDL-c: 156 mg/dL Vakkilainen et al, 2003 (31) GE Prospective longitudinal RCT 56 0 74…”
Davy, B. M., Davy, K. P., Ho, R. C., Beske, S. D., Davrath, L. R., & Melby, C. L. (2002) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/76.2.351 · Cited by 161
Cohn, J. S., Marcoux, C., & Davignon, J. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.10.2474 · Cited by 156
Apolipoprotein C-III, metabolic syndrome, and risk of coronary artery disease
Olivieri, O., Bassi, A., Stranieri, C., Trabetti, E., Martinelli, N., Pizzolo, F., Girelli, D., Friso, S., Pignatti, P. F., & Corrocher, R. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m300253-jlr200 · Cited by 139
Beyond Low-Density Lipoprotein Cholesterol
Mudd, J. O., Borlaug, B. A., Johnston, P. V., Kral, B. G., Rouf, R., Blumenthal, R. S., & Kwiterovich, P. O. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.07.045 · Cited by 136
Metabolic abnormalities: triglyceride and low-density lipoprotein
Krauss, R. M., & Siri, P. W. (2004) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2004.03.016 · Cited by 102
Self-citationPlasma and vessel wall lipoprotein lipase have different roles in atherosclerosis
Clee, S. M., Bissada, N., Miao, F., Miao, L., Marais, A. D., Henderson, H. E., Steures, P., McManus, J., McManus, B., LeBoeuf, R. C., et al. (2000) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)32399-3 · Cited by 101
ApoC-III gene polymorphisms and risk of coronary artery disease
Olivieri, O., Stranieri, C., Bassi, A., Zaia, B., Girelli, D., Pizzolo, F., Trabetti, E., Cheng, S., Grow, M. A., Pignatti, P. F., et al. (2002) · Journal of Lipid Research · doi:10.1194/jlr.m200145-jlr200 · Cited by 70
Olivieri, O., Martinelli, N., Sandri, M., Bassi, A., Guarini, P., Trabetti, E., Pizzolo, F., Girelli, D., Friso, S., Pignatti, P. F., et al. (2005) · Clinical Chemistry · doi:10.1373/clinchem.2004.040477 · Cited by 50
Halle, M., Berg, A., König, D., Keul, J., & Baumstark, M. W. (1997) · Metabolism · doi:10.1016/s0026-0495(97)90300-0 · Cited by 41
History and future of omega-3 fatty acids in cardiovascular disease
Sperling, L. S., & Nelson, J. R. (2016) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1120190 · Cited by 34
Annuzzi, G., Iovine, C., Mandarino, B., Patti, L., Di Marino, L., Riccardi, G., & Rivellese, A. A. (2001) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2001.00779.x · Cited by 13
Metadata
- Authors
- Mack, W. J., Krauss, R. M., & Hodis, H. N.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1996-05
- Volume
- 16
- Issue
- 5
- Pages
- 697-704
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2159389024
- Cited by
- 174
- References
- 6
- FWCI
- 14.59
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.